News

Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs

June 23, 2025

Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.

Abu Dhabi Department of Health Reaches Strategic Agreements During US Mission

June 20, 2025

The department’s newly announced partnerships were part of a weeklong visit that included discussions held at BIO 2025.

EIT Health Ireland–UK Expands European Network with Three New Members

June 19, 2025

NIBRT, Firefinch, and eg technology will join the center, adding to its collective of healthcare innovators.

Behind the Headlines, Episode 19: CGT Cost Pressures, BioNTech’s CureVac Move, and Spain’s CAR-T Model

June 19, 2025

Fabian Gerlinghaus, Alexander Seyf, and Knut Steffensen go behind the headlines and dive into the advanced therapy ecosystem.

BASF Opens GMP Manufacturing Facility in Michigan

June 19, 2025

The new facility offers cleanroom packaging and high-sensitivity analytical testing.

FDA Voucher Program Provides Shorter Drug Application Review Time

June 18, 2025

The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for shortened drug approval review time.

Mabion Announces Oncology Services Contest at BIO 2025

June 18, 2025

The contest, which aims to accelerate the development of recombinant protein-based oncology therapies, will culminate at CPHI Frankfurt in October 2025.

New Company Chrysalis Launches After Acquisition of Cleanroom Assets

June 17, 2025

Chrysalis lists among its partners early-stage biotechnology companies, contract research organizations, top-10 pharmaceutical firms, and various other life sciences stakeholders.

BIO 2025: Pulmonary Drug Delivery

June 16, 2025

PharmTech Group spoke with Andy Burns, vice-president of MDI Business Development at Kindeva, ahead of BIO 2025 to find out what’s new in pulmonary drug delivery.

AstraZeneca Partners on AI-Enabled Research with CSPC Pharmaceuticals

June 13, 2025

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule oral therapy for immunological diseases.